Replimune (REPL) Invested Capital (2019 - 2026)

Replimune has reported Invested Capital for 8 years, with the latest figure at $24.8 million in Q1 2026.

• Quarterly Invested Capital fell 2.88% year-over-year to $24.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100.3 million (down 2.65% YoY) and the FY2026 annual result came in at $24.8 million, down 2.88% from the prior year.
• Invested Capital declined to $24.8 million in Q1 2026 per REPL's latest filing, from $25.0 million in the prior quarter.
• Over five years, Invested Capital peaked at $27.0 million in Q1 2022 and troughed at $24.8 million in Q1 2026.
• A 5-year average of $26.0 million and a median of $26.1 million in 2024 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2026: Invested Capital declined 1.06% in 2022, then decreased 2.88% in 2026.
• Over 5 years, Invested Capital stood at $26.7 million in 2022, then dropped by 1.67% to $26.3 million in 2023, then decreased by 2.16% to $25.7 million in 2024, then declined by 2.73% to $25.0 million in 2025, then dropped by 0.8% to $24.8 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $24.8 million, $25.0 million, and $25.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.